The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Antibody Production Service Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 High-throughput Antibody Production Service
1.2.3 Small to Mid-scale Antibody Production Service
1.2.4 Large-scale Antibody Production Service
1.2.5 Chimeric Antibody Production Service
1.2.6 Antibody Fragment Production Service
1.2.7 Bispecific Antibody Production Service
1.2.8 Others
1.3 Market by Application
1.3.1 Global Recombinant Antibody Production Service Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical
1.3.3 Biotechnology Company
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Antibody Production Service Market Perspective (2018-2029)
2.2 Recombinant Antibody Production Service Growth Trends by Region
2.2.1 Global Recombinant Antibody Production Service Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Recombinant Antibody Production Service Historic Market Size by Region (2018-2023)
2.2.3 Recombinant Antibody Production Service Forecasted Market Size by Region (2024-2029)
2.3 Recombinant Antibody Production Service Market Dynamics
2.3.1 Recombinant Antibody Production Service Industry Trends
2.3.2 Recombinant Antibody Production Service Market Drivers
2.3.3 Recombinant Antibody Production Service Market Challenges
2.3.4 Recombinant Antibody Production Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Antibody Production Service Players by Revenue
3.1.1 Global Top Recombinant Antibody Production Service Players by Revenue (2018-2023)
3.1.2 Global Recombinant Antibody Production Service Revenue Market Share by Players (2018-2023)
3.2 Global Recombinant Antibody Production Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant Antibody Production Service Revenue
3.4 Global Recombinant Antibody Production Service Market Concentration Ratio
3.4.1 Global Recombinant Antibody Production Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Antibody Production Service Revenue in 2022
3.5 Recombinant Antibody Production Service Key Players Head office and Area Served
3.6 Key Players Recombinant Antibody Production Service Product Solution and Service
3.7 Date of Enter into Recombinant Antibody Production Service Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Antibody Production Service Breakdown Data by Type
4.1 Global Recombinant Antibody Production Service Historic Market Size by Type (2018-2023)
4.2 Global Recombinant Antibody Production Service Forecasted Market Size by Type (2024-2029)
5 Recombinant Antibody Production Service Breakdown Data by Application
5.1 Global Recombinant Antibody Production Service Historic Market Size by Application (2018-2023)
5.2 Global Recombinant Antibody Production Service Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Recombinant Antibody Production Service Market Size (2018-2029)
6.2 North America Recombinant Antibody Production Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Recombinant Antibody Production Service Market Size by Country (2018-2023)
6.4 North America Recombinant Antibody Production Service Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant Antibody Production Service Market Size (2018-2029)
7.2 Europe Recombinant Antibody Production Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Recombinant Antibody Production Service Market Size by Country (2018-2023)
7.4 Europe Recombinant Antibody Production Service Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Antibody Production Service Market Size (2018-2029)
8.2 Asia-Pacific Recombinant Antibody Production Service Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Recombinant Antibody Production Service Market Size by Region (2018-2023)
8.4 Asia-Pacific Recombinant Antibody Production Service Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recombinant Antibody Production Service Market Size (2018-2029)
9.2 Latin America Recombinant Antibody Production Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Recombinant Antibody Production Service Market Size by Country (2018-2023)
9.4 Latin America Recombinant Antibody Production Service Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Antibody Production Service Market Size (2018-2029)
10.2 Middle East & Africa Recombinant Antibody Production Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Recombinant Antibody Production Service Market Size by Country (2018-2023)
10.4 Middle East & Africa Recombinant Antibody Production Service Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 evitria SA
11.1.1 evitria SA Company Detail
11.1.2 evitria SA Business Overview
11.1.3 evitria SA Recombinant Antibody Production Service Introduction
11.1.4 evitria SA Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.1.5 evitria SA Recent Development
11.2 Bon Opus Biosciences
11.2.1 Bon Opus Biosciences Company Detail
11.2.2 Bon Opus Biosciences Business Overview
11.2.3 Bon Opus Biosciences Recombinant Antibody Production Service Introduction
11.2.4 Bon Opus Biosciences Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.2.5 Bon Opus Biosciences Recent Development
11.3 Biomatik
11.3.1 Biomatik Company Detail
11.3.2 Biomatik Business Overview
11.3.3 Biomatik Recombinant Antibody Production Service Introduction
11.3.4 Biomatik Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.3.5 Biomatik Recent Development
11.4 Biointron Biological Inc.
11.4.1 Biointron Biological Inc. Company Detail
11.4.2 Biointron Biological Inc. Business Overview
11.4.3 Biointron Biological Inc. Recombinant Antibody Production Service Introduction
11.4.4 Biointron Biological Inc. Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.4.5 Biointron Biological Inc. Recent Development
11.5 Sino Biological
11.5.1 Sino Biological Company Detail
11.5.2 Sino Biological Business Overview
11.5.3 Sino Biological Recombinant Antibody Production Service Introduction
11.5.4 Sino Biological Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.5.5 Sino Biological Recent Development
11.6 ProSci Inc
11.6.1 ProSci Inc Company Detail
11.6.2 ProSci Inc Business Overview
11.6.3 ProSci Inc Recombinant Antibody Production Service Introduction
11.6.4 ProSci Inc Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.6.5 ProSci Inc Recent Development
11.7 GenScript
11.7.1 GenScript Company Detail
11.7.2 GenScript Business Overview
11.7.3 GenScript Recombinant Antibody Production Service Introduction
11.7.4 GenScript Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.7.5 GenScript Recent Development
11.8 RayBiotech
11.8.1 RayBiotech Company Detail
11.8.2 RayBiotech Business Overview
11.8.3 RayBiotech Recombinant Antibody Production Service Introduction
11.8.4 RayBiotech Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.8.5 RayBiotech Recent Development
11.9 Cygnus Technologies
11.9.1 Cygnus Technologies Company Detail
11.9.2 Cygnus Technologies Business Overview
11.9.3 Cygnus Technologies Recombinant Antibody Production Service Introduction
11.9.4 Cygnus Technologies Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.9.5 Cygnus Technologies Recent Development
11.10 Cusabio Technology
11.10.1 Cusabio Technology Company Detail
11.10.2 Cusabio Technology Business Overview
11.10.3 Cusabio Technology Recombinant Antibody Production Service Introduction
11.10.4 Cusabio Technology Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.10.5 Cusabio Technology Recent Development
11.11 Absolute Antibody
11.11.1 Absolute Antibody Company Detail
11.11.2 Absolute Antibody Business Overview
11.11.3 Absolute Antibody Recombinant Antibody Production Service Introduction
11.11.4 Absolute Antibody Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.11.5 Absolute Antibody Recent Development
11.12 Cayman Chemical
11.12.1 Cayman Chemical Company Detail
11.12.2 Cayman Chemical Business Overview
11.12.3 Cayman Chemical Recombinant Antibody Production Service Introduction
11.12.4 Cayman Chemical Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.12.5 Cayman Chemical Recent Development
11.13 Creative Biolabs
11.13.1 Creative Biolabs Company Detail
11.13.2 Creative Biolabs Business Overview
11.13.3 Creative Biolabs Recombinant Antibody Production Service Introduction
11.13.4 Creative Biolabs Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.13.5 Creative Biolabs Recent Development
11.14 Promab Biotechnologies
11.14.1 Promab Biotechnologies Company Detail
11.14.2 Promab Biotechnologies Business Overview
11.14.3 Promab Biotechnologies Recombinant Antibody Production Service Introduction
11.14.4 Promab Biotechnologies Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.14.5 Promab Biotechnologies Recent Development
11.15 Leinco Technologies
11.15.1 Leinco Technologies Company Detail
11.15.2 Leinco Technologies Business Overview
11.15.3 Leinco Technologies Recombinant Antibody Production Service Introduction
11.15.4 Leinco Technologies Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.15.5 Leinco Technologies Recent Development
11.16 R&D Systems
11.16.1 R&D Systems Company Detail
11.16.2 R&D Systems Business Overview
11.16.3 R&D Systems Recombinant Antibody Production Service Introduction
11.16.4 R&D Systems Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.16.5 R&D Systems Recent Development
11.17 Rapid Novor
11.17.1 Rapid Novor Company Detail
11.17.2 Rapid Novor Business Overview
11.17.3 Rapid Novor Recombinant Antibody Production Service Introduction
11.17.4 Rapid Novor Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.17.5 Rapid Novor Recent Development
11.18 ACROBiosystems
11.18.1 ACROBiosystems Company Detail
11.18.2 ACROBiosystems Business Overview
11.18.3 ACROBiosystems Recombinant Antibody Production Service Introduction
11.18.4 ACROBiosystems Revenue in Recombinant Antibody Production Service Business (2018-2023)
11.18.5 ACROBiosystems Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details